We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $85.73 as of Dec 30th. NVO’s trailing and forward P/E were 28.92 and 21.98 respectively according to Yahoo Finance.
A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug.
Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema...
